TY - JOUR
T1 - Acinetobacter baumannii
T2 - Epidemiology, antimicrobial resistance, and treatment options
AU - Maragakis, Lisa L.
AU - Perl, Trish M.
N1 - Funding Information:
Potential conflicts of interest. T.M.P. has been on advisory boards for Pfizer, Replidyne, and 3M; has received recent research funding from 3M and Sage; and has received a speaker honorarium from Ortho McNeil. L.L.M.: no conflicts.
PY - 2008/4/15
Y1 - 2008/4/15
N2 - Multidrug-resistant Acinetobacter baumannii is recognized to be among the most difficult antimicrobial-resistant gramnegative bacilli to control and treat. Increasing antimicrobial resistance among Acinetobacter isolates has been documented, although definitions of multidrug resistance vary in the literature. A. baumannii survives for prolonged periods under a wide range of environmental conditions. The organism causes outbreaks of infection and health care-associated infections,including bacteremia, pneumonia, meningitis, urinary tract infection, and wound infection. Antimicrobial resistance greatly limits the therapeutic options for patients who are infected with this organism, especially if isolates are resistant to the carbapenem class of antimicrobial agents. Because therapeutic options are limited for multidrug-resistant Acinetobacter infection, the development or discovery of new therapies, well-controlled clinical trials of existing antimicrobial regimens and combinations, and greater emphasis on the prevention of health care-associated transmission of multidrug-resistant Acinetobacter infection are essential.
AB - Multidrug-resistant Acinetobacter baumannii is recognized to be among the most difficult antimicrobial-resistant gramnegative bacilli to control and treat. Increasing antimicrobial resistance among Acinetobacter isolates has been documented, although definitions of multidrug resistance vary in the literature. A. baumannii survives for prolonged periods under a wide range of environmental conditions. The organism causes outbreaks of infection and health care-associated infections,including bacteremia, pneumonia, meningitis, urinary tract infection, and wound infection. Antimicrobial resistance greatly limits the therapeutic options for patients who are infected with this organism, especially if isolates are resistant to the carbapenem class of antimicrobial agents. Because therapeutic options are limited for multidrug-resistant Acinetobacter infection, the development or discovery of new therapies, well-controlled clinical trials of existing antimicrobial regimens and combinations, and greater emphasis on the prevention of health care-associated transmission of multidrug-resistant Acinetobacter infection are essential.
UR - http://www.scopus.com/inward/record.url?scp=42549108748&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=42549108748&partnerID=8YFLogxK
U2 - 10.1086/529198
DO - 10.1086/529198
M3 - Review article
C2 - 18444865
AN - SCOPUS:42549108748
SN - 1058-4838
VL - 46
SP - 1254
EP - 1263
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 8
ER -